People · Operator
Named in public records as an officer, director or promoter · active 2009–2025 · Hospitals and Physicians, Pharmaceuticals, Manufacturing, Other Technology, Biotechnology, Other
| Company | Role | Sector | Stage | Raised · real | Value · est | Tied |
|---|---|---|---|---|---|---|
| Grand Rounds, Inc. | — | Hospitals and Physicians | Growth/Late | $904.4M | $289.9M | 2021 |
| Osteal Therapeutics, Inc. | — | Pharmaceuticals | Series C | $127.5M | $87.0M | 2020 |
| Terwilliger Partners, LLC | — | Manufacturing | Series C | $95.0M | $454.0M | 2018 |
| Misapplied Sciences, Inc. | — | Other Technology | Series A | $19.5M | $77.4M | 2019 |
| Medici Therapeutics, Inc. | — | Biotechnology | Series A | $14.8M | $39.7M | 2025 |
| Evidence Topco Ltd | — | Other | Series A | $8.2M | $111.3M | 2020 |
| BrainCells Inc | — | Pharmaceuticals | Series A | $7.2M | $127.0M | 2009 |
| GENIUS.COM Inc | — | Other Technology | Series A | $6.8M | $9.1M | 2009 |
| Culinary Health Innovations, LLC | — | Manufacturing | Seed | $2.3M | $2.8M | 2013 |
| Myelin Solutions, Inc. | — | Other Technology | Pre-Seed | $100K | $4.2M | 2018 |
David Thompson at the center, the companies they're named on, and every other operator named alongside them — an interlock map of shared founding teams, boards and funds. Name-matched, so treat as a research lead.
People named alongside David Thompson on the same companies — an interlock signal (shared founding team, board, or fund). Name-matched, so verify before acting.
| Operator | Shared | Their companies |
|---|---|---|
| David Miller | 1 | 29 |
| Bryan Roberts | 1 | 18 |
| Gordon Ritter | 1 | 8 |
| Carl Ledbetter | 1 | 7 |
| Mary Coleman | 1 | 6 |
| Renee Ryan | 1 | 6 |
| Nitin Khanna | 1 | 6 |
| Nancy Schoendorf | 1 | 5 |
| Carl Goldfischer | 1 | 5 |
| Douglas Kohrs | 1 | 4 |
| Roger J. Quy | 1 | 4 |
| Robbert Vorhoff | 1 | 4 |
| Bruce Shalett | 1 | 3 |
| Rushu Luo | 1 | 3 |
| Rick Gustafson | 1 | 3 |
| James A. Schoeneck | 1 | 3 |
| Paul Dietz | 1 | 3 |
| Martin Sands | 1 | 2 |
| Jason D. Levin | 1 | 2 |
| Benjamin Lambert | 1 | 2 |
People are matched by normalized name across records; a common name may merge distinct individuals. Treat as a research lead, the same way modeled valuations are directional, not quoted.